Market closedNon-fractional

MannKind/MNKD

13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX

About MannKind

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.

Ticker

MNKD

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Danbury, United States

Employees

413

MannKind Metrics

BasicAdvanced
$1.4B
Market cap
159.20
P/E ratio
$0.03
EPS
1.34
Beta
-
Dividend rate
$1.4B
1.34
3.835
3.285
-148.715
-161.705
1.06%
4.97%
-3.50%
159.2
6.02
-5.93
-5.85
435.42
74.92%
-111.42%
50.15%
-50.67%

What the Analysts think about MannKind

Analyst Ratings

Majority rating from 6 analysts.
Buy

MannKind Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
16.01% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$66M
13.36%
Net income
$11M
657.14%
Profit margin
16.01%
569.87%

MannKind Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 53.85%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.02
$0.01
-
$0.04
-
Expected
-$0.04
-$0.02
$0.00
$0.03
$0.01
Surprise
-47.37%
-160.61%
-
53.85%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for MannKind stock?

MannKind (MNKD) has a market cap of $1.4B as of July 05, 2024.

What is the P/E ratio for MannKind stock?

The price to earnings (P/E) ratio for MannKind (MNKD) stock is 159.2 as of July 05, 2024.

Does MannKind stock pay dividends?

No, MannKind (MNKD) stock does not pay dividends to its shareholders as of July 05, 2024.

When is the next MannKind dividend payment date?

MannKind (MNKD) stock does not pay dividends to its shareholders.

What is the beta indicator for MannKind?

MannKind (MNKD) has a beta rating of 1.34. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell MannKind stock

Buy or sell MannKind stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing